Basic Information
Based on its proprietary LentiFlash® technology and its manufacturing subsidiary Vectalys, the company has the potential to drive and advance the development of therapeutic methods mediated by RNA and DNA delivery for the treatment of a variety of diseases, including cancer, infectious diseases, and genetic disorders.
Flash Therapeutics
Toulouse,Oxitani,France
15~50 people
January 01, 2018
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios